FDA conditionally approves first drug for feline subclinical hypertrophic cardiomyopathy

FDA conditionally approves first drug for feline subclinical hypertrophic cardiomyopathy

Felycin-CA1 manages ventricular hypertrophy in feline patients with subclinical hypertrophic cardiomyopathy

TriviumVet Secures FDA Conditional Approval for First Treatment for Feline Cardiac Disease - Ireland South East

TriviumVet’s felycin®-CA1 has been granted conditional approval by the U.S. Food and Drug Administration (FDA) marking a significant milestone for the Waterford company and in feline cardiac care. This is the first approval for a feline cardiology drug and the first product approved for use in cats with HCM for any indication. felycin®-CA1 (sirolimus delayed release tablets), administered once weekly, is indicated for the management of ventricul…